

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**

### **宜明昂科生物醫藥技術（上海）股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1541)**

## **INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION OF CERTAIN UNLISTED SHARES OF THE COMPANY**

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the **“Company”**, together with its subsidiaries, the **“Group”**) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the **“Listing Rules”**) on The Stock Exchange of Hong Kong Limited (the **“Stock Exchange”**) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated October 25, 2024 in relation to the proposed participation in the H share full circulation programme by the Company and the “Guidelines on Application for ‘Full Circulation’ of Domestic Unlisted Shares of H-share Companies” (CSRC Announcement [2023] No. 50) (《H股公司境內未上市股份申請“全流通”業務指引》(中國證監會公告[2023]50號)) (the **“Guidelines”**) issued by the China Securities Regulatory Commission (the **“CSRC”**) on August 10, 2023 regarding the procedures of application by companies whose H shares are listed on the Stock Exchange for circulation of domestic unlisted shares (as defined under the Guidelines) on the Stock Exchange.

The board (the **“Board”**) of directors (**“Directors”**, and each a **“Director”**) of the Company is pleased to announce that the Company has recently received a filing notice issued by the CSRC (the **“Filing Notice”**) regarding the implementation of the H share full circulation of the Company. According to the Filing Notice, the Company has completed the filing with the CSRC in respect of the implementation of conversion up to an aggregate of 14,114,006 unlisted shares of the Company (the **“Unlisted Shares”**) into H shares of the Company (**“H Shares”**). The Filing Notice shall be valid for 12 months from March 11, 2025.

The information of the implementation of the H share full circulation of the Company is set forth in the table below.

No.	Name of Shareholders	Maximum number of Unlisted Shares to be converted
1.	Gongqing City Ruiji Fund III Investment Partnership (共青城瑞吉三期投資合夥企業(有限合夥))	3,463,672
2.	Sunshine Life Insurance Corporation Limited (陽光人壽保險股份有限公司)	3,350,655
3.	Shengzhou Minglang Industry Development Equity Investment Fund Partnership (Limited Partnership) (嵊州市銘朗產業發展股權投資基金合夥企業(有限合夥))	2,633,332
4.	Shanghai Sci-Tech Innovation Center Capital Fund I (Limited Partnership) (上海科創中心壹號股權投資基金合夥企業(有限合夥))	1,066,815
5.	Nanjing Xingjian Ruiying Equity Investment Partnership (Limited Partnership) (南京星健睿贏股權投資合夥企業(有限合夥))	1,697,445
6.	Gongqing City Chuangdongfang Huaying Equity Investment Partnership (Limited Partnership) (共青城創東方華盈股權投資合夥企業(有限合夥))	1,227,717
7.	Wuhu Bloomage Langya Healthcare Industry Investment Partnership (Limited Partnership) (蕪湖華熙朗亞健康產業投資合夥企業(有限合夥))	674,370
<b>Total</b>		<b><u>14,114,006</u></b>

The Company will apply to the Stock Exchange for the listing of, and permission to deal in, such H Shares on the Main Board of the Stock Exchange (the “**Conversion and Listing**”).

As at the date of this announcement, the details of implementation plan of the Conversion and Listing have not been finalized. The Company will make further announcements on the progress of the Conversion and Listing in compliance with the requirements under Listing Rules and the applicable laws, as and when appropriate.

**The Conversion and Listing are subject to other relevant procedures as required by the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**  
宜明昂科生物醫藥技術（上海）股份有限公司  
**Tian Wenzhi**  
*Chairman and Executive Director*

Hong Kong, March 14, 2025

*As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Guan Mei as executive Directors; (ii) Dr. Xu Cong as non-executive Director; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.*